Literature DB >> 21960869

Emerging agents for the medical therapy of hepatocellular carcinoma.

Josep Llovet1.   

Abstract

Entities:  

Year:  2007        PMID： 21960869      PMCID： PMC3099295     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

2.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

3.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 4.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

Review 5.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.